Press Releases Curasight A/S

Equities

CURAS

DK0061295797

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
11.5 ^DKK	+13.86%		+20.55%	-35.21%

May. 23	Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Curasight Q1 - Moving forward	May. 27	AQ
Interim report Q1 2024	May. 23	AQ
BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	Apr. 22	AQ
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	Apr. 16	AQ
Curasight announces change in the Board of Directors	Apr. 12	AQ
BioStock: Curasight cancels rights issue and evaluates alternative financing	Mar. 13	AQ
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	Mar. 11	AQ
Notice of Annual General Meeting 2024	Mar. 06	AQ
The subscription period in Curasight's rights issue begins today	Feb. 23	AQ
Curasight publishes information memorandum in connection with forthcoming rights issue	Feb. 22	AQ
Annual Report for the fiscal year 2023	Feb. 22	AQ
Year-end report October - December 2023	Feb. 22	AQ
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	Feb. 19	AQ
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	Feb. 13	PR
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	Feb. 13	AQ
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	Feb. 13	AQ
BioStock: Curasight gets first milestone payment from Curium	Feb. 02	AQ
Curasight A/S Achieves First Milestone under collaboration with Curium Inc.	Jan. 22	AQ
BioStock: Curasight gears up for phase II study in prostate cancer	Dec. 22	AQ
Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	Dec. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Curasight A/S

Equities

CURAS

DK0061295797

Press Releases

Filters